Regeneron Pharmaceuticals Q3 Adj. EPS $11.83 Beats $9.59 Estimate, Sales $3.754B Beat $3.585B Estimate

Author: Benzinga Newsdesk | October 28, 2025 05:30am
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $11.83 per share which beat the analyst consensus estimate of $9.59 by 23.38 percent. This is a 5.06 percent decrease over earnings of $12.46 per share from the same period last year. The company reported quarterly sales of $3.754 billion which beat the analyst consensus estimate of $3.585 billion by 4.71 percent. This is a 0.89 percent increase over sales of $3.721 billion the same period last year.

Posted In: REGN